Immunotherapy in allergic diseases - improved understanding and innovation for enhanced effectiveness
| Autor: | Nikolaos G. Papadopoulos, Paraskevi Xepapadaki, Michael Makris, Dimitrios Mitsias |
|---|---|
| Rok vydání: | 2020 |
| Předmět: |
0301 basic medicine
Allergen immunotherapy medicine.medical_treatment T-Lymphocytes Immunology Allergic inflammation 03 medical and health sciences 0302 clinical medicine Immune system Blocking antibody medicine Immunology and Allergy Animals Humans Receptor Asthma B-Lymphocytes Effector business.industry Immunotherapy Dendritic Cells medicine.disease Rhinitis Allergic 030104 developmental biology Desensitization Immunologic business 030215 immunology |
| Zdroj: | Current opinion in immunology. 66 |
| ISSN: | 1879-0372 |
| Popis: | Allergen immunotherapy leads to tolerance through multiple mechanisms that include tolerogenic dendritic cells and T and B regulatory cells. These induced cellular populations produce mediators to skew the immune response to a tolerogenic milieu that, among others, results in IgG4 blocking antibodies formation and lowered FcE receptors. All lead in decreased effector responses from mast cells, eosinophils, and basophils thus limiting the allergic inflammation. Clinically, this results in better allergic rhinitis control and, of importance, asthma prevention. Newer approaches include modified allergens, second generation adjuvants/carriers and routes of administration, all aiming to increased efficacy with parallel no compromise of safety. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect